印度制药领袖要求更快的批准和改革, 以促进创新, Indian pharma leaders demand faster approvals and reforms to boost innovation and compete globally amid rising delays.

印度制药领导人呼吁紧急进行监管改革,以推动创新,从非专利药物转向高价值药物开发,理由是推迟临床试验批准,将研究工作推向海外。 Indian pharmaceutical leaders are calling for urgent regulatory reforms to boost innovation and shift from generics to high-value drug development, citing delays in clinical trial approvals that push research overseas. 他们强调需要更快的批准、更好的基础设施和更强大的工业-学术界伙伴关系,警告印度在全球竞争力方面有可能落后于中国。 They stress the need for faster approvals, better infrastructure, and stronger industry-academia partnerships, warning India risks falling behind China in global competitiveness. 同时,林业发展局启动了一项检查前试点方案,以简化药物制造审查,目的是通过早期合作和检查减少延误和加强国内生产。 Meanwhile, the FDA has launched a pre-check pilot program to streamline drug manufacturing reviews, aiming to reduce delays and strengthen domestic production through early collaboration and inspections.